OpGen and Merck’s ILÚM Health Solutions to Host Event at VIII International Symposium on Hospital Acquired Infections and ...
March 25 2019 - 7:30AM
OpGen, Inc. (Nasdaq: OPGN) announced today it will host an event
with ILÚM Health Solutions, LLC (“ILÚM”), a wholly owned subsidiary
of Merck’s Healthcare Services and Solutions, at the VIII
International Symposium on Hospital Acquired Infections and
Antimicrobial Stewardship, held March 27-29 at the Intercontinental
Hotel in Santiago de Cali, Colombia. Both companies are sponsors of
the conference and will have an exhibit.
Event Details:
Title: “Strengthening the Power of Antimicrobial
Stewardship through Rapid Diagnostics and Clinical Decision Support
Solutions” Day: Wednesday, March 27Time: 9:00am-12:00pm (Colombia
Standard Time)Location: Salón Río Lilis on the 2nd floor of the
Intercontinental Hotel
“We look forward to returning to Colombia to
discuss the urgent global issue of antimicrobial stewardship with
the leading health and medical minds from Latin America,” said Evan
Jones, Chairman and Chief Executive Officer of OpGen. “As the
threat from antibiotic-resistant bacteria and hospital acquired
infections continues to grow worldwide, it remains crucial for
healthcare organizations to identify innovative solutions, like
those from OpGen and ILÚM, to fight, prevent, and contain the
spread of multidrug-resistant pathogens.”
Both companies will showcase their products
to key opinion leaders from major healthcare institutions in
Colombia as well as other Latin American countries, such as
Argentina, Brazil, Chile, Guatemala, Mexico and Peru. OpGen will
present its QuickFISH®, Acuitas® AMR Gene Panel, and Acuitas
Lighthouse® solutions. ILÚM will present Insight, a
smartphone-based clinical decision support solution for
antimicrobial stewardship and infection control that was developed
under a Centers for Disease Control and Prevention (CDC) contract
and in partnership with OpGen and Universidad El Bosque of Bogota,
Colombia.
About ILÚMILÚM Health Solutions
is a provider of technology and services to support precision
medicine for infectious disease management, clinical
decision-support and precision antibiotic therapy. ILÚM is part of
Healthcare Services & Solutions, LLC, a
wholly-owned subsidiary of Merck & Co., Inc. Its Insight
solution and other portfolio products are commercially available
and in use in major health systems. For more information,
visit www.ILÚMhealthsolutions.com.
About OpGen
OpGen, Inc. is a precision medicine company
harnessing the power of molecular diagnostics and informatics to
help combat infectious disease. We are developing molecular
information products and services for global healthcare settings,
helping to guide clinicians with more rapid and actionable
information about life threatening infections, improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs.
Our molecular diagnostics and informatics
products, product candidates and services combine our Acuitas
molecular diagnostics and Acuitas Lighthouse informatics
platform for use with our proprietary, curated MDRO knowledgebase.
We are working to deliver our products and services, some in
development, to a global network of customers and
partners. The Acuitas AMR Gene Panel (RUO) is intended
for Research Use Only and is not for use in diagnostic procedures.
The Acuitas Lighthouse Software is not distributed commercially for
antibiotic resistance prediction and is not for use in diagnostic
procedures. For more information, please
visit www.opgen.com.
OpGen, Acuitas, and Acuitas
Lighthouse are registered trademarks of OpGen, Inc.
OpGen Contact: Michael Farmer Vice President,
Marketing (240)
813-1284mfarmer@opgen.comInvestorRelations@opgen.com
Press Contact:Matthew BretziusFischTank
Marketing and PRmatt@fischtankpr.com
Investor Contacts: Joe GreenEdison
Groupjgreen@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024